Oftalmol Zh.2012;4:78-84.

Full text Pdf 



A. Sergiienko, L. Lytvynchuk, G. Lavrenchuk

Kyiv, Ukraine

The efficacy of intravitreal injections of anti-VEGF in the case of choroidal neovascularization (CNV) due to pathologic myopia becomes apparent in particular with decreasing of membrane's dimensions. The authors have investigated antiproliferative and apoptotic action of anti-VEGF agents (ranibizumab, bevacizumab, pegaptanib) on fibroblast-like cell strain L929 in vitro (testing model of CNV cellular matrix in vitro). Cultivation of investigated drugs with cellular culture was held according to standard protocol. During investigation cellular vital indices were evaluated (survival, mitotic activity, polycariocyte index). Analysis of cellular apoptosis level was evaluated as well. Cultivation of cellular culture L929 with anti-VEGF agents has provoked depression of cellular vital indices that was manifested with decrease of survival, mitotic index and increase of polycariocytes, which are signs of cellular reproductive death. Apoptosis has increased as a result of action of all drugs. Antiproliferative and apoptotic effects were dependent on drug's doses. Obtained results reveal and approve an alternative actions of anti-VEGF drugs on fibroblast-like cells: depression of mitotic activity and apoptosis increase.


1.Животная клетка в культуре (Методьі и применение в биотехнологии) / под общ. ред. проф. Дьяконова Л. П. — М.: Изд-во «Спутник+», 2009. — 656с.

2.L-929 (NCTC-clone 929,Clone of strain L) (Connective tissue, mouse) // http://www.viromed.com/services/product/l929.htm.

3.Bngela Carneirob Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells / Bngela Carneirob, Manuel Falcrob, Ana Pirracoa, Paula Milheiro-Oliveirac, Fernando Fal-cro-Reisb, and Raquel Soaresa // Elsevier Ltd, 2008. — С. 246- 279.

4.Biswas P. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration / Biswas P., Sengupta S., Choudhary R., Home S., Paul A., Sinha S. // Indian J Ophthalmol. — 2011. — V.59 (3). — P.191-6.

5.Bennett M. D. Pegaptanib for myopic choroidal neovas-cularization in a young patient / Bennett M. D., Yee W. // Graefes Arch Clin Exp Ophthalmol. —   2007. — Jun; 245 (6). — P.903-5.

6.Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. M. S. Spitzer, B. Wallenfels Thilo, A. Sierra, E. Yoeruek, S. Peters, S. Henke-Fahle, K. U. Bartz-Schmidt, P. Szurman on behalf of the Tue-bingen Bevacizumab Study Group // Br J Ophthalmol. — 2006. — V.90. — P.1316-1321.

7.Gharbiya M. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumaba randomized controlled trial / Gharbiya M.,Giustolisi R., Allievi F., Fantozzi N., Mazzeo L., Scavella, Gabrieli C. B. // Am J Ophthalmol. — 2010. — Mar; 149 (3). — P.458-64.

8.Lai T. Y. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia / Lai T. Y., Chan W. M., Liu D. T., Lam D. S. // Retina. — June 2009. — V.29 (6). — C-750-6.

9.Daniel Lorenzo Intravitreal Ranibizumab for Choroidal Neovascularization Secondary to Pathological Myopia: 12-Month Follow-Up / Daniel Lorenzo Luis Arias, Rafel Alcubierre, Octavio Pujol, J. M. Caminal, Marcos Rubio, Jaume Catak, Pere Garcia-Bru, Jorge Amiga // Ophthalmologica. — 2011. — V.226. — P.103- 109.

10.Martin S. Spitzer Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macu-gen) and ranibizumab (Lucentis) on different ocular cells / Martin S. Spitzer, Efdal Yoeruek, Ana Sierra, Barbara Wallenfels-Thilo, Ulrich Schraermeyer, Bernhard Spitzer, Karl U. Bartz-Schmidt, Peter Szurman // Graefe's Arch Clin Exp Ophthalmol. — 2007. — V.245. — P.1837-1842.

11.Neruban Kumaran. Long-term remission of myopic choroidal neovascular membrane after treatment with ranibi-zumab: a case report / Neruban Kumaran, Dawn A. Sim and Adnan Tufail // Journal of Medical Case Reports. — 2009. — C.1186/1752- 1947- 3-84.

12.Spitzer S. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells / M. S. Spitzer, B. Wallenfels-Thilo, A. Sierra, E. Yoeruek, S. Peters, S. Henke-Fahle, K. U. Bartz-Schmidt, P. Szurman, on be¬half of the Tuebingen Bevacizumab Study Group // Br J Ophthalmol. — 2006. — V.90. — P.1316-1321.

13.Salvatore Grisanti, M. D. Bevacizumab: Off-label use in Ophthalmology/ Salvatore Grisanti, M.D., Focke Ziems-sen, M.D. // Indian Journal of Ophthalmology. — 2007. — С-55; 217-20.

14.Freshney I., Animal cell culture, A practical approach, IRL Press Oxford-Washington DC // http://www.rlsnet. ru/tn_index_id_40825.htm#sostav-i-forma-vypuska.

15.Kaempf Stefanie, Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture / Kaempf Stefanie, Johnen Sandra, Salz Anna Katharina, Weinberger An¬dreas, Walter Peter, Thumann Gabriele // Invest ophthal-mol & Visual Sci. — 2008. — vol. 49, no7. — P.3164-3171.

16.Scupola A., Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy, A case report / Scupola A. L. Ventura, A. C. Tib-erti, D. D'Andrea and E. Balestrazzi // Graefe's archive for clinical and exp ophthalmol. — 2004. — V.242, N7. — P.605-610.

17.Tong J. P., Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovas-cularizatio / Tong J. P., Chan W. M., Liu D. T., Lai T. Y Choy K. W., Pang C. P., Lam D. S. // Am J Ophthalmol. —  2006. — Mar; 141 (3). — P.456- 62.

18.Hooshang Faghihi. Optical Coherence Tomographic Findings in Highly Myopic Eyes / Hooshang Faghihi, Fedra Hajizadeh, Mohammad Riazi-Esfahani // J Ophthalmic Vis Res. — 2010. — 5 (2). — P.110-121.